UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042907
Receipt number R000048980
Scientific Title Study on the AGEs-reducing effects induced by test food intakes
Date of disclosure of the study information 2022/01/07
Last modified on 2021/09/14 22:55:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the AGEs-reducing effects induced by test food intakes

Acronym

Study on the AGEs-reducing effects induced by test food intakes

Scientific Title

Study on the AGEs-reducing effects induced by test food intakes

Scientific Title:Acronym

Study on the AGEs-reducing effects induced by test food intakes

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate AGEs-reducing effects associated with 12 weeks daily ingestion of the test food.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Advanced glycation-end products

Key secondary outcomes

1. Blood sugar level on empty stomach
2. HbA1c
3. Changes in clinical test values


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

No need to know


Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of the test food 1 twice a day for 12 weeks.

Interventions/Control_2

Ingestion of the test food 2 twice a day for 12 weeks.

Interventions/Control_3

Ingestion of the placebo food twice a day for 12 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Males/females ranging in age from 20 to 64 at informed consent.
(2) Subjects equipped with no more than 6.4% of HbA1c.
(3) Subjects who have no difficulty in ingesting the test food twice a day.
(4) Subjects who have no difficulty in receiving the test food twice a week.
(5) Subjects who can give informed consent to participate in this trial after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) Subjects with some kind of continuous medical treatment.
(2) Subjects who are now under the restriction of carbohydrate with dieting (losing some weight by exercises and meal-controlling), and/or are planning to go on a diet, during this trial.
(3) All through this trial, subjects who have any difficulty in refraining from taking steadily (not less than three times a week) in the health-specific/functional/supplementary/health foods, which might affect the test results.
(4) Subjects who are planning to change their lifestyle.
(5) Subjects with extremely irregular eating habits.
(6) Subjects having not less than once a week
, restricting their mealtimes to no more than once a day, within the last three months.
(7) Subjects who extremely take alcohol.
(8) Pregnant, possibly pregnant, or lactating women.
(9) Subjects having present/previous medical history of serious diseases in heart, liver, kidney, and/or digestive organs.
(10) Subjects with drug and/or food allergies, especially in wheat, eggs and milk.
(11) Subjects who are now under the other clinical tests with some kind of medicine/food, or took part in those within four weeks before this trial, or are planning to participate in those after giving informed consent to take part in this trial.
(12) Subjects who donated over 200 mL of their whole blood and/or blood components within a month before this trial.
(13) Males who donated over 400 mL of their whole blood within the last three months before this trial.
(14) Females who donated over 400 mL of their whole blood within the last four months before this trial.
(15) Males who will be collected over 1200 mL of their blood within the last twelve months before this trial.
(16) Females who will be collected over 800 mL of their blood within the last twelve months before this trial.
(17) Others who have been determined as ineligible for participation, according to the principal/sub investigator's opinions.

Target sample size

21


Research contact person

Name of lead principal investigator

1st name Suguru
Middle name
Last name Fujiwara

Organization

CPCC Company Limited

Division name

Division of Clinical Research

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ichinohe

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Nisshin Seifun Group Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 01 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 12 Month 01 Day

Date of IRB

2020 Year 11 Month 20 Day

Anticipated trial start date

2021 Year 01 Month 07 Day

Last follow-up date

2021 Year 04 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 01 Month 05 Day

Last modified on

2021 Year 09 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048980